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Bortezomib inhibits nuclear factor-kB (NF-kB). Cetuximab is a chimeric mouse–human antibody targeted against epidermal growth
factor receptor (EGFR). We hypothesised that concomitant blockade of NF-kB and EGFR signalling would overcome
EGFR-mediated resistance to single-agent bortezomib and induce apoptosis through two molecular pathways. The aim of this
phase I trial was to establish the maximum tolerated dose (MTD) for bortezomib plus cetuximab in patients with EGFR-expressing
epithelial tumours. The 21-day treatment cycle consisted of bortezomib administered on days 1 and 8 through dose escalation
(1.3–2mgm
 2). Cetuximab was delivered at a dose of 250mgm
 2 on days 1, 8 and 15 (400mgm
 2 day 1 cycle 1). A total of 37
patients were enroled and given a total 91 cycles. No grade X3 haematological toxicity was noted. Non-hematological grade X3
toxicities included fatigue (22% of patients), dyspnoea (16%) and infection (11%). The MTD was not reached at the highest tested
bortezomib dose (2.0mgm
 2). Efficacy outcomes included disease progression in 21 patients (56.7%) and stable disease (SD) at 6
weeks in 16 patients (43.3%). Five of the six patients with SD at 12 weeks were diagnosed with cancers of the lungs or head and neck.
This combination therapy was moderately effective in extensively pretreated patients with non-small cell lung or head and neck
cancers and warrants further investigation.
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Single-agent targeted therapy has proven effective in blocking the
growth and spread of many different tumour types. However, one
of the main causes of its limited application in cancer treatment is
that most tumours are not dependent on a single molecular
pathway and are capable of circumventing single-target inhibition
through the development of several mechanisms of resistance.
Earlier efforts to slow the emergence of resistance have been
achieved with combinations of traditional chemotherapies.
Similarly, combinations of targeted agents acting on different
molecular pathways involved in cancer pathogenesis may provide
not only an additive effect, but may also lead to apoptotic synergy
and delay the onset of resistance.
Of the vast number of possible combinations of targeted agents,
preclinical data suggest that there could be a potential benefit from
combining bortezomib and cetuximab (Cascone et al, 2008; Sloss
et al, 2008; Wagenblast et al, 2008; Wagenblast et al, 2009).
Bortezomib is the first drug in a new class of targeted therapies
called proteasome inhibitors. The mechanism of action of
bortezomib is not entirely known. Bortezomib inhibits the orderly
degradation of cellular proteins by the ubiquitin–proteasome
pathway, leading to the inactivation of the anti-apoptotic
transcriptional regulator, nuclear factor-kB (NF-kB) (Rajkumar
et al, 2005). Inactivation of NF-kB could be one of the mechanisms
by which bortezomib induces cell-cycle arrest and apoptosis in
solid tumours (Mitsiades et al, 2006). Other mechanisms in non-
hematological malignancies may include induction of apoptosis by
Bim and Bik protein upregulation (Li et al, 2008), reduction of
bcl-2 levels (Mortenson et al, 2005), induction of NOXA protein
(Fribley et al, 2006) or reactive oxygen species generation (Ling
et al, 2003). Subtoxic concentrations of bortezomib potently
sensitise multiple myeloma cell lines to DNA-damaging chemo-
therapeutic agents, including cells resistant to these drugs
(Mitsiades et al, 2003). Bortezomib also abolishes cell adhesion-
mediated drug resistance. Consistent with these preclinical
data, bortezomib has been effective in clinical trials for
myeloma (Richardson et al, 2003, 2005; Jagannath et al, 2004)
and responses have been documented in solid tumours, including
renal cancer (Kondagunta et al, 2004), small cell and non-small cell
lung cancer (Lara et al, 2006a,b), and prostate cancer (Hainsworth
et al, 2007).
Cetuximab is a chimeric mouse–human antibody targeted
against epidermal growth factor receptor (EGFR). Competitive
binding of cetuximab to EGFR prevents ligand-induced tyrosine
kinase activation and induces receptor downregulation. In clinical
trials, cetuximab is active in colorectal cancer (Rosenberg et al,
2002; Cunningham et al, 2004; Folprecht et al, 2004; Lenz et al,
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s2004; Rougier et al, 2004; Saltz et al, 2004) and in concomitant
treatment with radiotherapy in head and neck cancer (Bonner
et al, 2006). Upregulation of cell-surface EGFR by bortezomib was
indicated in earlier studies and recently reported in squamous-cell
cancer lines (Lorch et al, 2007). This observation strongly suggests
that bortezomib could sensitise cancer cells to EGFR inhibition.
However, another preclinical study has reported that the
combination of a tyrosine kinase inhibitor (TKI) and bortezomib
resulted in nearly complete NF-kB blockade and synergistically
inhibited the proliferation of renal cancer cells, but only when TKI
exposure occurred first or simultaneously with bortezomib
exposure (An and Rettig, 2007). Pretreatment with bortezomib
resulted in incomplete NF-kB blockade and had an antagonistic
effect on proliferation. Thus, the activity of combination therapy
could be schedule-dependent, and concomitant administration of
both drugs could be the most optimal schedule, with the important
caveat that schedule-dependent effects could vary by tumour type
given the broad range of signalling events affected by bortezomib.
The combined activity of bortezomib and cetuximab in EGFR-
positive solid cancers is unknown, though it is reasonable to
postulate that this combination could be synergistic, given the
preclinical observations that bortezomib upregulates EGFR
expression in cancer cells. Although bortezomib and cetuximab
have been studied extensively as single agents, the potential for
combining the two agents has not been systematically explored.
This Phase I dose-escalation study was designed to evaluate the
safety and tolerability of combination bortezomib and cetuximab,
and characterize the preliminary effectiveness of the drug
combination in patients with refractory solid tumours expressing
EGFR.
PATIENTS AND METHODS
Study design
This study was designed as a prospective, single-center, dose-
escalation phase I study at the University of Minnesota Masonic
Cancer Center. The primary objective was to determine the
maximum tolerated dose (MTD) of bortezomib, when given with a
fixed dose of cetuximab, in the treatment of patients with solid
tumours expressing EGFR. The secondary objective was to obtain
preliminary information regarding the anti-tumor activity of
bortezomib and cetuximab, when given in combination. The study
was reviewed and approved by University of Minnesota Institu-
tional Review Board. Each patient provided written informed
consent before participation. This trial was registered at the
US National Institutes of Health (http://www.clinicaltrials.gov),
unique identifier NCT00622674.
Patient eligibility
All patients were X18 years old with histologically confirmed
advanced solid cancer refractory to standard treatment and at least
one EGFR-positive tumour specimen determined by immuno-
histochemical staining. Expression of EGFR was assessed by
pathologists at the University of Minnesota. An ECOG perfor-
mance status of 0–1 and a life expectancy of at least 12 weeks were
required. Earlier systemic chemotherapy, immunotherapy or
biological therapy was allowed, except for earlier treatment with
bortezomib and/or cetuximab. Patients were required to complete
earlier radiation or systemic therapy at least 14 days before study
entry and at least 30 days for investigational agents. Any grade 41
toxicity had to be resolved before study enrolment. Adequate
organ function within 14 days of study enrolment was required,
including adequate bone marrow reserve: absolute neutrophil
count (ANC) X1.5 10
9l
 1, platelets 4100 10
9l
 1 and haemo-
globin 49g per 100ml, and hepatic function: bilirubin o1.5 times
the upper limit of normal ( ULN), alkaline phosphatase (ALP),
aspartate transaminase (AST) and alanine transaminase (ALT)
o3.0 ULN (ALP, AST and ALT o5 ULN was acceptable if liver
had tumour involvement). A calculated or measured creatinine
clearance of 430mlmin
 1 was required within 14 days before
enrolment. Disease status had to be that of measurable or non-
measurable disease, as defined by RECIST criteria.
Treatment schedule
The treatment schedule consisted of a 21-day cycle with
bortezomib given on days 1 and 8 and cetuximab given on days
1, 8 and 15 until unresolved dose-limiting toxicity (DLT), disease
progression (DP) or a maximum of six cycles was completed. For
all treatment cycles, bortezomib was administered before cetux-
imab on days 1 and 8. Day 1 treatment was administered only in
patients with an ANC X1500mm
 3 and platelets X100000mm
 3.
Doses were recalculated before each treatment cycle on the basis of
the patient’s body surface area. Bortezomib was given at several
escalating doses by intravenous (i.v.) push over 3–5s followed by
a standard saline flush or through a running i.v. line. Patients
received cetuximab as an i.v. infusion through infusion pump or
gravity drip. The infusion rate never exceeded 10mgmin
 1.A
loading dose of cetuximab (400mgm
 2) was infused over 90min
on day 1, cycle 1 followed by a maintenance dose of 250mgm
 2
infused over 60min on days 8 and 15 of cycle 1 and days 1, 8 and
15 of subsequent cycles. Premedication with H1 antagonists was
given before each dose of cetuximab.
Bortezomib was provided by a partial sponsor of the study,
Millenium Pharmaceuticals (Cambridge, MA, USA), and released
through the Investigational Pharmacy of the University of
Minnesota (Minneapolis, MN, USA).
Bortezomib dose escalation
Eight dose levels were studied with a minimum of three patients in
each dose level. The starting dose of bortezomib was 1.3mgm
 2
with 0.1 increment increases with each successive dose level up to a
maximum of 2.0mgm
 2. All patients within a dose level had to
complete a minimum of one cycle of treatment and experience no
DLT before the next group of three patients could be enroled in the
next higher dose level. If one DLT occurred in cycle 1, three
additional patients had to be treated at the same dose level and all
complete the first cycle without DLT.
Toxicity was assessed during the first cycle. Dose escalation for
subsequent cycles in the same patient (intra-patient dose
escalation) was not permitted. DLT was defined as treatment-
related grade X4 haematological toxicity or grade X3 non-
hematological toxicity occurring in the first cycle of therapy. DLT
was also defined as the delay of the start of cycle 2 treatment by
more than 3 weeks because of incomplete haematological recovery
(ANC p1500mm
3 or platelets p100000mm
3) or unresolved non-
hematological X2 toxicity. Adverse events were classified accord-
ing to NCI’s Common Terminology Criteria for Adverse Events V
3.0 (CTCAE). If two or more DLTs occurred at a given dose level,
the dose just below would define the MTD and would be
considered the recommended dose for future phase II trials.
Efficacy assessment and follow-up care
Restaging procedures, including imaging studies, were carried out
during the 30-day period before starting therapy and after every
two cycles of treatment (every 6 weeks). Study follow-up was
halted after the completion of six cycles of therapy, because the
primary end point was to assess safety and establish the maximally
tolerated dose. Patients benefiting from therapy were given the
choice of continuing beyond 6 cycles.
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sStatistical methods
Comparisons between the groups with different EGFR expression,
and analysis of skin rash correlation with response, were carried
out using the Fisher’s exact test for categorical variables.
RESULTS
Patient characteristics
A total of 37 patients were enroled in this study between November
2005 and August 2008. The majority of patients were male (62.9%),
had an ECOG performance status of 1 (51.4%), were diagnosed
with lung cancer (40%) and had received more than two types of
earlier systemic therapy (62.9%). Patient characteristics are
summarised in Table 1.
Bortezomib dose-escalation findings
At least three patients were enroled at each dose level of
bortezomib. A DLT was first observed in one of three patients in
cohort 4 (1.6mgm
 2), but was not observed in the next three
patients at the same dose level. This patient developed grade 3
nausea, mucositis, vomiting, dehydration and dysphagia in the
first cycle of therapy. The only other DLT was seen in cohort 8
(2mgm
 2), in a patient who developed respiratory failure because
of pneumonia and died after the first cycle of therapy. This patient
was the twelfth of the 13 patients enroled in cohort 8, the highest
dose level of bortezomib. Two patients in cohort 8 also developed
grade 4 urticaria on day 1 of cycle 1 and could not be re-exposed to
cetuximab. These two patients were replaced because allergic and
anaphylactic reactions to cetuximab are well-known and do not
constitute a DLT. No MTD was reached in the study.
Toxicity assessment
Overall, the regimen of bortezomib and cetuximab was well-
tolerated. A total of 91 cycles of therapy was administered with a
median of two cycles per patient (range: 1–6). Three patients
completed six cycles (8.1%). Treatment delays were required in 23
patients (62%) because of low platelet count or other non-
hematological symptoms, such as Gram-negative bacteremia,
constipation, neuropathic pain, fatigue or muscle weakness.
All treatment-related grade X3 toxicities are presented in
Table 2. No subject in the trial developed grade 3 or 4
haematological toxicity. The most common grade 1 and 2
haematological side effects were decreased haemoglobin (54% of
patients) and lymphopenia (22% of patients). All grade 3 or 4
toxicities were non-hematological in origin, the most common of
which were fatigue (22% of patients), dyspnoea (16%), infection
(11%), dehydration (11%), constipation (8%), nausea (8%) and
muscle weakness (5%). Grade 3 cellulitis was observed at
1.3mgm
 2 in a 58-year-old male patient with pyriform sinus
cancer. Renal failure occurred in two patients at doses of 1.5 and
1.9mgm
 2. At the higher dose, renal failure was fatal for a 52-year-
old female with bladder cancer. The most commonly observed
grade 1 and 2 non-hematological side effects were fatigue (81% of
patients), skin rash (78%), anorexia (57%), vomiting (54%),
nausea (51%), constipation (51%), diarrhoea (49%), peripheral
neuropathy (35%), infection (22%) and dyspnoea (16%).
Tumour response
Of the 37 enroled patients, only four patients (10.8%) had stable
disease (SD) after six cycles. Stable disease was achieved in six
patients (16.2%) after four cycles and in 16 patients (43.3%) after
two cycles. Disease progression was observed in 21 patients
(56.7%) after two cycles and in 28 patients (75.6%) after four
cycles. Response data is not available for three patients who
withdrew before completing the first cycle of therapy. Stable
disease was seen at different dose levels: 1.3, 1.4, 1.5, 1.9 and
2mgm
 2. Although SD was seen in different cancer types, five of
the six patients were diagnosed with cancers of the lungs or head
and neck. One other patient experiencing SD was diagnosed with
skin cancer. The degree of EGFR staining did not correlate with
response (P¼0.562) (Table 3). Although SD was seen in 50% of
patients with skin rash and only 12.5% without, the presence of
skin rash did not correlate significantly with SD (P¼0.104).
DISCUSSION
In this first phase I study of bortezomib with cetuximab, the MTD
was not achieved in the range of tested doses. An earlier phase I
study established the DLT for single-agent, once weekly bortezo-
mib at 2mgm
 2 (Papandreou et al, 2004). Therefore, we believe
Table 1 Patient characteristics
n¼37
Median age 56 (range: 31–68)
Gender
Male 24 (64.9%)
Female 13 (35.1%)
Race
Caucasian 32 (86.5%)
Asian 4 (10.8%)
Black 1 (2.7%)
Primary tumour site
Lung 16 (43.2%)
Head/neck 6 (16.2%)
Kidney 4 (10.8%)
Pancreas 3 (8.1%)
Bladder 2 (5.4%)
Skin 1 (2.7%)
Oesophagus 1 (2.7%)
Ovary 1 (2.7%)
Appendix 1 (2.7%)
Prostate 1 (2.7%)
Ureter 1 (2.7%)
Lung cancer histology
Adenocarcinoma 11 (29.7%)
Adenosquamous cell 1 (2.7%)
Squamous cell 2 (5.4%)
Small cell 2 (5.4%)
ECOG status
0 18 (48.6%)
1 19 (51.4%)
Earlier systemic therapy
0 1 (2.7%)
1 8 (21.6%)
2 4 (10.8%)
3 and more 24 (64.9%)
Earlier surgery
Yes 21 (56.8%)
No 16 (43.2%)
Earlier radiotherapy
Yes 20 (54%)
No 17 (46%)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
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sthat combination of bortezomib and cetuximab can be used safely
at the highest recommended doses for each single agent tested.
None of the haematological toxicities experienced by our patient
population were serious (only grade 1/2). In addition, the expected
toxicities related to cetuximab were predominantly grade 1 or 2
(skin rash and diarrhoea reported in 81 and 51% of patients,
respectively), and these did not worsen in frequency or grade by
the addition of bortezomib.
In our study, no patient achieved complete or partial response,
and only six patients experienced SD for at least 12 weeks. A total
of 28 subjects had progressive disease, which is a disappointing
outcome. A key finding of our study, which warrants further
investigation, is that every patient who achieved a clinical benefit
was diagnosed with either cancer of the lungs or head and neck.
These responses were seen throughout different dose levels of
bortezomib. The identification of another disease marker could
possibly enrich the study population with potential responders for
subsequent clinical trials of this combination of targeted agents.
Recent data of lack of response of K-ras-mutated colorectal
tumours to cetuximab (Karapetis et al, 2008) may help rationalise
the use of this selection criteria in future studies with bortezomib
and cetuximab. Another observation, perhaps not surprising in
view of the colorectal data (Chung et al, 2005), is that there was no
apparent correlation between patient responses and intensity of
EGFR expression. Our goal in requiring EGFR expression was to
exclude malignancy without an EGFR target, and thus, patients
who would not benefit from cetuximab. Since the initiation of our
study, it has become clear that response to EGFR-targeted therapy
is not correlated with EGFR overexpression in the context of
colorectal carcinoma (Chung et al, 2005). None of our patients in
this study, however, had colorectal carcinoma. The current
standard of not testing colorectal tumours for EGFR expression
may not apply for other epithelial tumour histologies. It is possible
that low serum ligand levels of EGF or TGFa would correlate better
with response, as suggested by one study (Han et al, 2009). Recent
phase II and III trials have shown that the presence of a K-ras
mutation in tumours predicts response to EGFR-targeted therapy
(Allegra et al, 2009). Intensive research, attempting to correlate the
benefits from EGFR-targeted therapy with EGFR presence, EGFR
mutation (NSCLC), EGFR gene amplification (NSCLC), EGFR
pathway dependence or downstream mutations (conveying
resistance to EGFR therapy, such as K-ras mutation in colorectal
Table 2 Grade X3 toxicity for each bortezomib dose level
Incidence of toxicity
b
Dose
(mgm
 2)
No. of
patients
No. of cycles
a
(median, range) Patients (%) Cycles (%)
Toxicity type/grade
(total no. of patients, cycles)
1.3 3 11 (4, 1–6) 2 (67) 6 (55) Fatigue G3 (1, 2)
Infection G3 (2, 4)
Haemorrhage G4 (1, 1)
Acneiform rash G3 (1, 1)
Muscle weakness G3 (1, 2)
Peripheral neuropathy G3 (1, 2)
Hypocalcaemia G3 (1, 1)
Hypophosphataemia G3 (1, 1)
Chills G3 (1, 1)
1.4 3 6 (2, 1–3) 2 (67) 2 (33) Dyspnoea G3 (1, 1)
Constipation G3 (1, 1)
1.5 3 9 (2, 1–6) 2 (67) 2 (22) Hyperkalaemia G3 (1, 1)
BUN elevation G3 (1, 1)
Mucositis G4 (1, 1)
Vomiting G3 (1, 1)
Low bicarbonates G3 (1, 1)
Creatinine elevation G4 (1, 1)
1.6 6 17 (4, 1–4) 3 (50) 4 (24) Fatigue G3 (2, 2)
Dyspnoea G3 (2, 2)
Vomiting (1, 1)
Dehydration G3 (1, 1)
Dysphagia G3 (1, )1
1.7 3 6 (2, 2–2) 2 (67) 3 (50) Fatigue G3 (2, 2)
Infection G3 (1, 1)
Pain G3 (1, 2)
AST elevation G3 (1, 1)
Infection G3 (1, 1)
1.8 3 6 (2, 2–2) 2 (67) 2 (33) Muscle weakness G3 (1, 2)
1.9 3 13 (4, 3–6) 2 (67) 3 (23) Fatigue G3 (1, 1)
Constipation G3 (1, 2)
Dehydration G3 (2, 1)
Abdominal pain G3 (1, 1)
Anorexia G3 (1, 1)
Nausea G3 (1, 1)
Death G5 (1, 1)
2.0 13 23 (2, 1–4) 9 (69) 10 (43) Fatigue G3 (3, 3)
Infection G3 (1, 1)
Dyspnoea G3 (3, 4)
Constipation G3/4 (1, 2)
Dehydration G3 (1, 1)
Nausea G3 (2, 2)
Diarrhoea G3 (1, 1)
Dizziness G3 (1, 1)
Peripheral neuropathy G3 (1, 1)
Low blood pressure G3 (1, 1)
Death G5 (1, 1)
Abbreviations: AST¼aspartate transaminase; BUN¼blood urea nitrogen.
aAt least two visits out of five were completed per cycle.
bIncidence of grade 1/2 toxicities was 100%
for all patients at all dose levels; one patient who tolerated six cycles (1.9mgm
 2) did not experience any toxicities during two of these cycles.
Table 3 EGFR staining and response
After 2 weeks of treatment
(two cycles)
EGFR-positive stain PD SD
15 1
25 8
39 6
Abbreviations: EGFR¼epidermal growth factor receptor; PD¼progressive disease;
SD¼stable disease.
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scarcinoma) is currently underway, and most likely will provide
different answers for different cancer histologies.
In conclusion, treatment with bortezomib and cetuximab
resulted in a tolerable toxicity profile at the highest dose level of
bortezomib tested. The MTD was not reached. Although our study
tested concomitant administration, the optimal timing of both
drugs administration remains to be determined and could be
influenced by tumour type. We propose using bortezomib at a
dose of 2mgm
 2 on days 1 and 8 combined with immediate
administration of cetuximab at a 400mgm
 2 loading dose on
day 1, followed by 250mgm
 2 weekly, in future phase II trials of
epithelial cancers.
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